RESEARCH
Home Introduction Divisions Organized Research Units Research Training Program Selected Scholarly Interests

Patricia W. Finn, MD. Department Chair

© Copyright 2014 The Board of Trustees of the University of Illinois

David J. Peace, M.D.


Academic Title: Professor of Medicine                                                                         

Administrative Positions: Director, Hematology and Medical Oncology Training Program

Division: Hematology and Oncology

Location: 840 S. Wood St., Suite 820-E (MC 713), Chicago, IL 60612

Phone: (312)413-1507 (Office) Fax: (312)413-4131

E-mail: dpeace@uic.edu


Education:

MD, University of Pittsburgh, Pittsburgh, PA (1980)

Resident, Presbyterian University Hospital, Pittsburgh, PA (1980-1983)

Fellow, University of Washington, Seattle, WA (1984-1988)


Faculty Positions:


Clinical Specialties


Research Interests


Selected Publications

1. Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Hoffman R and Sossman J. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31patients with hematologic malignancies. Bone Marrow Transplant. 32(5):471-6, 2003.

2. Van Besien K, Mehra R, Wadehra N, Stock W, Khouri I, Giralt S, Devine S, Wickrema A, Peace D, Sosman J, Gajewski J and Champlin R. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 10(6):386-94, 2004.

3. Perambakam SM, Srivastava R and Peace DJ. Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate cancer. Clin. Immunol. 117(1):94-9, 2005.

4. Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, Mahmud D, Nunez R, Sosman JA and Peace DJ. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol .Immunother. 55(9):1033-42, 2005.

5. Saraf S, Chen YH, Dobogai LC, Mahmud N, Peace D, Saunthararajah Y, Hoffman R, Chunduri S and Rondelli D. Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplant. 37(12):1099-102, 2006.

6. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N, Quigley J, Hoffman R, Jessop E, Beri R and Rondelli D. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 38(7):477-82, 2006.

7. Margolin KA, van Besien K and Peace DJ. An introduction to foundation and industry-sponsored research: practical and ethical considerations. Hematology Am. Soc. Hematol. Educ. Program. 2007:498-503, 2007.

8. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH, Mahmud N, Hurter E, Beri R and Rondelli D. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant. 41(11):935-40, 2008.

9. Rosenbaum C, Peace D, Rich E, and Van Besien K. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. Biol. Blood Marrow Transplant. 14(6):719-23, 2008.

10. Alagiozian-Angelova V, Xu G, Peace D and Gaitonde S. Aggressive primary splenic CD5 positive/Cyclin D1 negative B-cell lymphoma in a patient with chronic hepatitis B virus infection. Acta. Oncol. 47(8):1613-5, 2008.

11. Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC, Shord S, Quigley JG, Chen YH, Mahmud N and Rondelli D. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant. 45(2):249-53, 2010.

12. Podberezin M, Angeles R, Guzman G, Peace D and Gaitonde S. Primary pancreatic sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): an unusual extranodal manifestation clinically simulating malignancy. Arch. Pathol. Lab. Med. 134(2):276-8, 2010.

13. Perambakam S, Xie H, Edassery S and Peace DJ. Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154). Clin. Dev. Immunol . 2010:473453, 2010.

14. Hacker ED, Larson J, Kujath A, Peace D, Rondelli D and Gaston L. Strength training following hematopoietic stem cell transplantation. Cancer Nurs. 34(3):238-49, 2011.

15. Hacker ED, Larson JL and Peace D. Exercise in patients receiving hematopoietic stem cell transplantation: lessons learned and results from a feasibility study. Oncol. Nurs. Forum. 38(2):216-23, 2011.

16. Saraf SL, Patel P, Ozer H, Peace DJ, Quigley JG, Mahmud N and Rondelli D. Improved outcomes with novel agents and auto-SCT for multiple myeloma in African-American patients. Bone Marrow Transplant. 48(2):319-20, 2013.